{"filing":{"accession_number":"0001104659-26-117948","cik":"0001455365","ticker":"CGTX","company_name":"COGNITION THERAPEUTICS INC","form":"8-K","filing_date":"2026-10-22","report_date":"2026-10-22","primary_document":"tm2628101d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465926117948/tm2628101d1_8k.htm"},"events":[{"id":36949,"run_id":34063,"accession_number":"0001104659-26-117948","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The disclosure announces FDA alignment on key design elements (patient selection, dose, duration, endpoints) for a Phase 3 pivotal trial of zervimesine in dementia with Lewy bodies. This is a material regulatory and clinical milestone for a clinical-stage biopharmaceutical company, representing progress toward a registrational study in an indication with no approved treatments. While not a specific named event type, this is clearly an operational/strategic advancement in the company's clinical development program that would affect a reasonable investor's assessment of the registrant's prospects.","company_name":"COGNITION THERAPEUTICS INC","ticker":"CGTX","filing_date":"2026-10-22","form":"8-K","submitted_at":null,"items":[{"id":41514,"accession_number":"0001104659-26-117948","item_number":"8.01","item_title":"Results of Operations and Financial Condition.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces FDA alignment on key design elements (patient selection, dose, duration, endpoints) for a Phase 3 pivotal trial of zervimesine in dementia with Lewy bodies. This is a material regulatory and clinical milestone for a clinical-stage biopharmaceutical company, representing progress toward a registrational study in an indication with no approved treatments. While not a specific named event type, this is clearly an operational/strategic advancement in the company's clinical development program that would affect a reasonable investor's assessment of the registrant's prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-22T10:09:54.225651+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":41514,"accession_number":"0001104659-26-117948","item_number":"8.01","item_title":"Results of Operations and Financial Condition.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces FDA alignment on key design elements (patient selection, dose, duration, endpoints) for a Phase 3 pivotal trial of zervimesine in dementia with Lewy bodies. This is a material regulatory and clinical milestone for a clinical-stage biopharmaceutical company, representing progress toward a registrational study in an indication with no approved treatments. While not a specific named event type, this is clearly an operational/strategic advancement in the company's clinical development program that would affect a reasonable investor's assessment of the registrant's prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-22T10:09:54.225651+00:00","company_name":"COGNITION THERAPEUTICS INC","ticker":"CGTX","filing_date":"2026-10-22"}]}